Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery

Clinical Infectious Diseases

Volumn 58, Issue 9, 2014, Pages 1312-1321

  Engsig, Frederik N ^a,b   Zangerle, Robert ^c   Katsarou, Olga ^d   Dabis, Francois ^e   Reiss, Peter ^f,g   Gill, John ^h   Porter, Kholoud ⁱ   Sabin, Caroline ^j   Riordan, Andrew ^k   Fätkenheuer, Gerd ^l   Gutiérrez, Félix ^m   Raffi, Francois ⁿ   Kirk, Ole ^a,o   Mary Krause, Murielle ^p   Stephan, Christoph ^q   De Olalla, Patricia Garcia ^r   Guest, Jodie ^s   Samji, Hasina ^t   Castagna, Antonella ^u   D'arminio Monforte, Antonella ^v   Skaletz Rorowski, Adriane ^w   Ramos, Jose ^x   Lapadula, Giuseppe ^y   Mussini, Cristina ^z   Force, Lluís ^aa   Meyer, Laurence ^ab   Lampe, Fiona ^j   Boufassa, Faroudy ^p   Bucher, Heiner C ^ac   De Wit, Stéphane ^ad   Burkholder, Greer A ^ae   Teira, Ramon ^af   Justice, Amy C ^ag,ah   Sterling, Tim R ^ai   M Crane, Heidi ^aj   Gerstoft, Jan ^a   Grarup, Jesper ^o   May, Margaret ^ak   Chêne, Geneviève ^e   Ingle, Suzanne M ^ak   Sterne, Jonathan ^ak   Obel, Niels ^a   more..

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d LAIKO GENERAL HOSPITAL   (Greece)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g STICHTING HIV MONITORING   (Netherlands)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ MRC CLINICAL TRIALS UNIT   (United Kingdom)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^l UNIVERSITY OF COLOGNE   (Germany)

^m HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

ⁿ HÔTEL DIEU   (France)

^o UNIVERSITY OF COPENHAGEN   (Denmark)

^p INSERM   (France)

^q UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^r AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

^s Veterans Affairs Medical Center   (Georgia)

^t BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^u SAN RAFFAELE HOSPITAL   (Italy)

^v SAN PAOLO HOSPITAL   (Italy)

^w RUHR UNIVERSITY BOCHUM   (Germany)

^x HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^y UNIVERSITY OF MILANO BICOCCA   (Italy)

^z UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^aa HOSPITAL DE MATARÓ   (Spain)

^ab BICÊTRE HOSPITAL   (France)

^ac UNIVERSITY HOSPITAL BASEL   (Switzerland)

^ad SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^ae University of Alabama at Birmingham   (United States)

^af Hospital de Sierrallana Torrelavega   (Spain)

^ag VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^ah YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ai VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^aj UNIVERSITY OF WASHINGTON   (United States)

^ak UNIVERSITY OF BRISTOL   (United Kingdom)

more..

Author keywords

CD4 cell recovery; HIV; mortality; risk factors; sustained viral suppression

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; VIRUS ANTIBODY; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ADULT DISEASE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HEPATITIS C VIRUS; HETEROSEXUAL MALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; VIRUS LOAD; VIRUS TRANSMISSION; ADDICTION; CAUSE OF DEATH; COMPLICATION; HETEROSEXUALITY; HIV INFECTIONS; MIDDLE AGED; STATISTICAL MODEL; TRANSMISSION;

ADULT; ANTI-HIV AGENTS; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HETEROSEXUALITY; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS; SUBSTANCE-RELATED DISORDERS; VIRAL LOAD;

EID: 84898883876     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu038     Document Type: Article

References (32)

1. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95
2. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96
3. The CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000; 355:1158-9
4. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441-6
5. Baker JV, Peng G, Rapkin J, et al. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr 2008; 48:541-6
6. Hughes RA, Sterne JA, Walsh J, et al. Long-Term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. HIV Med 2011; 12:583-93
7. Grabar S, Le MV, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-10
8. Engsig FN, Gerstoft J, Kronborg G, et al. Long-Term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: A cohort study. BMC Infect Dis 2010; 10: 318
9. Young J, Psichogiou M, Meyer L, et al. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: A longitudinal cohort study from COHERE. PLoS Med 2012; 9:e1001194
10. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360:119-29
11. deWolf F, Sabin C, Kirk O, Thorne C, Chene G, Porter K. Developing a multidisciplinary network for clinical research on HIV infection: The EuroCoord experience. Clin Invest 2012; 2:255-64
12. Gill J, May M, Lewden C, et al. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-96
13. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509
14. Rubin D. Inference and missing data. Biometrika 1976; 63:581-92
15. National Institutes of Health. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2013. Available at: Http://aidsinfo.nih.gov/guidelines. Accessed 28 October 2013
16. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: Analysis of prospective studies. Lancet 2003; 362:679-86
17. Lanoy E, May M, Mocroft A, et al. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 2009; 23:2199-208
18. Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-Term CD4T lymphocyte response to potent antiretroviral therapy. AIDS 2002; 16:359-67
19. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17:1907-15
20. Florence E, Lundgren J, Dreezen C, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003; 4:255-62
21. Dion ML, Bordi R, Zeidan J, et al. Slow disease progression and robust therapy-mediated CD4+ T-cell recovery are associated with efficient thymopoiesis during HIV-1 infection. Blood 2007; 109: 2912-20
22. Yamashita TE, Phair JP, Munoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15:735-46
23. Khoury G, Rajasuriar R, Cameron PU, Lewin SR. The role of naive Tcells in HIV-1 pathogenesis: An emerging key player. Clin Immunol 2011; 141:253-67
24. Loutfy MR, Genebat M, Moore D, et al. A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr 2010; 55:451-9
25. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): A prospective cohort study. Lancet Oncol 2009; 10:1152-9
26. Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22:2143-53
27. Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and non-Acquired immunodeficiency syndromedefining malignancies. Cancer 2010; 116:5306-15
28. Gascon RL, Narvaez AB, Zhang R, et al. Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion. J Acquir Immune Defic Syndr 2002; 30:146-53
29. Kuller LH, Tracy R, BellosoW, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203
30. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-106
31. Abrams D, Levy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548-59
32. Khanna N, Opravil M, Furrer H, et al. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clin Infect Dis 2008; 47:1093-101.